HYBRID EVENT: Join us in person in London, UK or attend virtually from anywhere.
Paediatric Primary Immunodeficiency (PID) represents a complex and heterogeneous group of inherited disorders characterized by defects in the immune system, rendering affected children highly susceptible to recurrent and severe infections. This category of disorders encompasses a myriad of genetic mutations that disrupt the proper functioning of various components of the immune system, such as T cells, B cells, phagocytes, and complement proteins. The clinical spectrum of PID is vast, ranging from mild and easily treatable conditions to severe and life-threatening diseases. Children with PID often present with frequent respiratory, gastrointestinal, and skin infections, which can be recurrent, unusually severe, or caused by uncommon pathogens. Additionally, some forms of PID manifest with autoimmune phenomena, allergies, and an increased risk of malignancies. Early diagnosis of PID is crucial for timely intervention, but its complexity often leads to diagnostic delays. Advances in genetic testing and immunological assays have significantly improved the accuracy and speed of diagnosis, enabling healthcare providers to tailor specific therapeutic strategies. Treatment modalities for PID include immunoglobulin replacement therapy, prophylactic antibiotics, and, in some cases, hematopoietic stem cell transplantation. Collaborative efforts between Paediatricians, immunologists, and geneticists are essential for comprehensive care and ongoing research aimed at understanding the underlying genetic and immunological mechanisms of PID, paving the way for more effective therapies and improved outcomes for affected children. Overall, the management of Paediatric Primary Immunodeficiency demands a multidisciplinary approach, emphasizing early detection, personalized treatment plans, and ongoing monitoring to optimize the long-term health and quality of life for these vulnerable Paediatric patients.
